Related Experiment Video
Updated: Jul 13, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy
Tara Anne Collidge1, Peter Campbell Thomson, Patrick Barry Mark
1Renal Unit and Radiology Department, Glasgow Royal Infirmary, Castle Street, 3rd Floor Walton Bldg, Glasgow G4 0SF, Scotland.
Insights
Gadolinium-based contrast agents are associated with nephrogenic systemic fibrosis in dialysis patients. Higher cumulative doses and more frequent administration increased the risk of developing this condition.
Area of Science:
- Nephrology
- Radiology
- Toxicology
Background:
- Nephrogenic systemic fibrosis (NSF) is a debilitating condition linked to gadolinium-based contrast agents (GBCAs).
- Dialysis-dependent patients with established renal failure are particularly vulnerable to NSF.
- Understanding the relationship between GBCA exposure and NSF is crucial for patient safety.
Purpose of the Study:
- To compare GBCA administration frequency and cumulative dose in dialysis patients who developed NSF versus those who did not.
- To investigate the association between GBCA exposure parameters and NSF development.
Main Methods:
- Retrospective analysis of adult dialysis patients in West Scotland (2000-2006).
- Recorded diagnoses of NSF, GBCA-enhanced MRI episodes, and cumulative GBCA doses.
- Analyzed outcomes using parametric and nonparametric statistical tests.
Main Results:
- 14 out of 1826 patients developed NSF.
- Patients with NSF were significantly more likely to have undergone GBCA-enhanced MRI (93% vs 22.5%, P<.001).
- NSF patients received higher median cumulative doses of gadodiamide (0.39 vs 0.23 mmol/kg, P=.008) and more GBCA-enhanced MR imaging sessions.
Conclusions:
- GBCA administration is positively associated with NSF development in patients with renal failure.
- Higher cumulative doses of gadodiamide and increased dosing events correlate with increased NSF risk.
Purpose:
To retrospectively compare the frequency of administration and cumulative dose of gadolinium-based contrast agent in dialysis-dependent patients who did and those who did not develop nephrogenic systemic fibrosis.
Materials And Methods:
The ethics committees granted exempt status for this study and also waived the need for informed consent. A retrospective analysis was performed of all adult patients undergoing dialysis in the west of Scotland between January 1, 2000, and July 1, 2006. Diagnoses of nephrogenic systemic fibrosis, episodes of gadolinium-enhanced magnetic resonance (MR) imaging, and cumulative doses of gadolinium-based contrast agent were recorded. Outcomes were analyzed by means of parametric and nonparametric testing.
Results:
Fourteen of 1826 patients had a diagnosis of nephrogenic systemic fibrosis. Mortality was similar for affected and nonaffected patients. Thirteen (93%) of 14 patients with nephrogenic systemic fibrosis had undergone gadolinium-enhanced MR imaging compared with 408 (22.5%) of 1812 nonaffected patients (P<.001). Patients with nephrogenic systemic fibrosis received a higher median cumulative dose of gadodiamide (0.39 vs 0.23 mmol per kilogram of body weight, P=.008) and underwent more gadolinium-enhanced MR imaging than their nonaffected gadolinium-exposed counterparts.
Conclusion:
The data support a positive association between gadolinium-based contrast agent administration and development of nephrogenic systemic fibrosis in the established renal failure population; in addition, there is a positive association between cumulative dose of gadodiamide used and dosing events.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
